Study identifier:D1441C00125
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Seroquel on glucose metabolism
schizophrenia
Phase 4
No
Seroquel (quetiapine)
All
572
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient’s glucose metabolism
Location
Location
Burgas, Bulgaria
Location
Sofia, Bulgaria
Location
Ruse, Bulgaria
Location
Varna, Bulgaria
Location
Dobjany, Czech Republic
Location
KLADNO, Czech Republic
Location
Opava, Czech Republic
Location
Praha 10, Czech Republic
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.